Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Jnj-41443532. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 known ✓ | P41597 | 19/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Jnj-41443532 SCHEMBL3334626 | 1.00 | CCR2 (0.98) | CCR2KCNH2 | |
| Jnj-41443532 SCHEMBL3334620 | 1.00 | CCR2 (0.98) | CCR2KCNH2 | |
| Jnj-41443532 SCHEMBL2485329 | 0.99 | CCR2 (1.00) | CCR2KCNH2 | |
| Jnj-41443532 SCHEMBL29420518 | 0.99 | CCR2 (1.00) | CCR2KCNH2 | |
| Jnj-41443532 SCHEMBL13302364 | 0.99 | CCR2 (1.00) | CCR2KCNH2 | |
| Jnj-41443532 SCHEMBL2545786 | 0.99 | CCR2 (1.00) | CCR2KCNH2 | |
| Jnj-41443532 SCHEMBL2485331 | 0.99 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL745630 | 0.94 | CCR2 (0.90) | CCR2KCNH2 | |
| SCHEMBL748703 | 0.94 | CCR2 (0.90) | CCR2KCNH2 | |
| SCHEMBL17056662 | 0.92 | CCR2 (0.87) | CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376475-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| US-8450304-B2 | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCRL2 | CCR2 1/4885KCNH2 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.